Search

The goal of the project is to test and develop an herbal face pack that contains natural herbal compounds that act as antioxidants, antiseptics, and skin brighteners. Natural herbal components including coffee, multani mitti, arjuna powder, rice flour, gram flour, orange peel powder, nutmeg, milk powder, saffron, aloe vera gel. All natural components were sieved through #120 mesh, carefully weighed, and geometrically blended for a homogeneous formulation, and then tested for phytochemical, morphological, physical, stability, and irritancy, microbial as well as physicochemical properties. Herbal face masks or packs are used to revitalize muscles and improve blood circulation while maintaining healthy skin and eliminating pollutants from pores. All face pack formulations were determined to be good in physical criteria and clear of skin irritations, indicating that the face packs have good qualities, according to this report's results. To identify the practical aids of face packs for human consumption as cosmetic items, more optimization research are needed on this study.

The research aimed to produce an herbal facial scrub. The majority of times, the skin on the face is in regular contact with dirt, pollution, and other contaminants. The scrub comprises various natural components that are safe to use, have fewer adverse effects, and have antibacterial, anti-infective, antioxidant, anti-aging, and moisturizing characteristics. The primary ingredient in this scrub is coffee. Coffee contains a lot of antioxidant properties. In addition, coffee grounds have a different aroma and a coarse grain and can be used to remove dirt skin cells that have died. The scrub was made with a simple mixing procedure and a variety of materials, including coffee beans, nutmeg, masoor dal, corn starch, and coconut oil mixed in melted beeswax. Other ingredients such as glycerine, light liquid paraffin, stearic acid, tween 80, and a perfuming agent was added to this formulation with effective results.

In summary, the past several years have shown an increase in the quality of trials examining the clinical efficacy of various CAM modalities for pain conditions. There is still need to raise the quality of the studies from a scientific and methodological point of view in many areas of CAM research by randomization, appropriate sample size, blinding, and developing more sophisticated sham procedures. However, much work still has to be done to find ways to preserve the clinical authenticity of CAM treatment methods when brought into the light of a research protocol. Recent attempts have been made to find a method of maintaining the standardization and reproducibility of research protocols while allowing the kind of flexible treatment that would normally be applied in a clinical setting. Other questions that should be answered with future studies include understanding how treatment length influences outcome, if maintenance treatments are needed for chronic conditions, and cost and risk comparisons with standard pharmacological treatment. Providing this kind of detail will assist both with reproducibility as well as help us gain a better understanding about whether certain treatment paradigms are superior to others for specific clinical conditions. Finally, physicians who have an interest in pursuing CAM research should educate themselves both about the methodological issues inherent with the particular area of interest as well as about ways to maintain the authenticity of the CAM treatment protocols so that the literature is not populated with more poorly designed studies. With the emerging interest in integrative medicine, there is a growing interest in collaboration and a greater number of physicians are interested in obtaining training in CAM modalities to help bridge this gap between CAM and conventional clinicians. For example, the American Academy of Medical Acupuncturists (AAMA) has been formed to help as both an educational and research forum for physician acupuncturists and the American Holistic Medical Association provides educational exposure in a broad range of Integrative and CAM modalities. The future of medicine will likely be Integrative and the more health care providers can educate themselves about this area of medicine, the better they will be able to provide the highest quality of care to their patients.

SummaryStudies in North America and Europe indicate that the prevalence of blood-borne viruses (BBVs) is elevated in individuals with severe mental illness; there are no comparable data for the UK. We offered routine testing for HIV, and hepatitis B and C in an inner-London in-patient psychiatric unit as a service improvement. Of the patients approached 83% had mental capacity to provide informed consent for testing and 66% of patients offered testing accepted. Although it was not our objective to establish the prevalence of BBVs, 18% of patients had serological evidence of a current or previous BBV infection, we found that offering routine testing in an in-patient psychiatric setting is both practical and acceptable to patients.

Bortezomib (Velcade, formerly PS-341) is proteasome inhibitor with documented antitumor activity in multiple myeloma and other lymphoid malignancies. We performed a Phase I study to investigate the maximum tolerated dose and dose-limiting toxicity of bortezomib in patients with acute leukemias refractory to or relapsing after prior therapy. Fifteen patients were treated with 0.75 (n = 3), 1.25 (n = 7), or 1.5 (n = 5) mg/m2 bortezomib administered twice weekly for 4 weeks every 6 weeks. Dose-limiting toxicity included orthostatic hypotension (n = 2), nausea (n = 2), diarrhea (n = 1), and fluid retention (n = 1), all at 1.5 mg/m2 bortezomib. Proteasome inhibition was dose dependent and reached 68% at 1.5 mg/m2 bortezomib. Peak inhibition was observed 1 h after treatment and returned to near baseline levels by 72 h after treatment. Incubation of blast cells with bortezomib in vitro showed induction of apoptosis in three of five patients investigated. We conclude that the maximum tolerated dose of bortezomib in patients with acute leukemia is 1.25 mg/m2, using a twice-weekly for 4 weeks every 6 weeks schedule. The in vitro evidence of antileukemia and transient hematological improvements observed in some patients warrants further investigation of bortezomib in acute leukemias, probably in combination with other agents.